PMID- 16846404
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20060718
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 60
IP  - 7
DP  - 2006 Jul
TI  - Closing the gap between clinical research and clinical practice: can outcome 
      studies with thiazolidinediones improve our understanding of type 2 diabetes?
PG  - 873-83
AB  - Recent clinical research has provided a wealth of information to support optimal 
      management strategies in type 2 diabetes mellitus (T2DM). In particular, outcome 
      studies appropriately have had an increasingly important impact on clinical 
      decision-making. Additional, new data are required, however, to close the current 
      gaps in clinical knowledge and improve patient outcomes in T2DM. These outcome 
      studies are particularly important in assessing the long-term benefit of newer 
      agents for which data are available for short-term glycaemic control, effects on 
      lipids and some data on non-traditional cardiovascular risk markers, but outcome 
      data for harder end points relevant to the natural history of T2DM, particularly 
      beta-cell function, are lacking. Outcome studies such as ADOPT and DREAM are 
      investigating the impact of thiazolidinediones (TZDs) on beta-cell function and 
      disease progression in T2DM and impaired glucose tolerance, respectively, the 
      results of which are eagerly anticipated. The primary focus of this article is on 
      TZD outcome studies evaluating beta-cell function and disease progression.
FAU - Goldstein, B J
AU  - Goldstein BJ
AD  - Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical 
      College of Thomas Jefferson University, Philadelphia, PA 19107-6799, USA. 
      Barry.Goldstein@jefferson.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Angiopathies/etiology
MH  - Disease Progression
MH  - Glucose Intolerance/etiology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin-Secreting Cells/physiology
MH  - Life Style
MH  - Risk Factors
MH  - Thiazolidinediones/*therapeutic use
MH  - Treatment Outcome
RF  - 76
EDAT- 2006/07/19 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/07/19 09:00
PHST- 2006/07/19 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/07/19 09:00 [entrez]
AID - IJCP1018 [pii]
AID - 10.1111/j.1742-1241.2006.01018.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2006 Jul;60(7):873-83. doi: 10.1111/j.1742-1241.2006.01018.x.